Home testing kits, coordinated outreach improve CRC screening rates

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a phase III clinical trial by researchers at City of Hope.

May 02, 2025

Vol.51 No.17

Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

April 25, 2025

Vol.51 No.16

By Richard M. Goldberg

Clinical Roundup

Disasters likely delay early cancer diagnoses, study shows

Rates of colorectal cancer diagnoses dropped during and shortly after Hurricanes Irma and Maria and the COVID-19 pandemic in Puerto Rico, according to a recent analysis led by investigators at the University of Puerto Rico.

April 18, 2025

Vol.51 No.15

Clinical Roundup

Gene-based blood test for melanoma may detect early signs of cancer return

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a recent study led by researchers at NYU Langone Health and its Perlmutter Cancer Center shows.

April 18, 2025

Vol.51 No.15

In Brief

CRUK and partners pledge £5.5m funding for colorectal cancer research

Cancer Research UK and partners on March 31 committed £5.5 million in funding to form a research team tasked with making personalized medicine a reality for people with colorectal cancer. The initiative is designed to unite research expertise and solve unanswered questions about the disease.

April 04, 2025

Vol.51 No.13

Drugs & Targets

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

Exact Sciences Corp. announced the launch of Cologuard Plus, the most accurate noninvasive colorectal cancer screening test reported in studies to date. FDA-approved for average-risk patients 45+ and covered by Medicare, the Cologuard Plus test detects 95% of colorectal cancers at 94% specificity in the U.S. screening population.

April 04, 2025

Vol.51 No.13

Home testing kits, coordinated outreach improve CRC screening rates

YOU MAY BE INTERESTED IN

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

Regulation must keep up with scientific advances

Disasters likely delay early cancer diagnoses, study shows

Gene-based blood test for melanoma may detect early signs of cancer return

CRUK and partners pledge £5.5m funding for colorectal cancer research

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

Renew today!

Subscriber content

Never miss an issue!

Login